CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma von Advani, Ranjana, Flinn, Ian, Popplewell, Leslie, Forero, Andres, Bartlett, Nancy L, Ghosh, Nilanjan, Kline, Justin, Roschewski, Mark, LaCasce, Ann, Collins, Graham P, Tran, Thu, Lynn, Judith, Chen, James Y, Volkmer, Jens-Peter, Agoram, Balaji, Huang, Jie, Majeti, Ravindra, Weissman, Irving L, Takimoto, Chris H, Chao, Mark P, Smith, Sonali M

Volltext

Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody von Dominguez, George A, Condamine, Thomas, Mony, Sridevi, Hashimoto, Ayumi, Wang, Fang, Liu, Qin, Forero, Andres, Bendell, Johanna, Witt, Robert, Hockstein, Neil, Kumar, Prasanna, Gabrilovich, Dmitry I

Volltext

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer von Ma, Cynthia X, Gao, Feng, Luo, Jingqin, Northfelt, Donald W, Goetz, Matthew, Forero, Andres, Hoog, Jeremy, Naughton, Michael, Ademuyiwa, Foluso, Suresh, Rama, Anderson, Karen S, Margenthaler, Julie, Aft, Rebecca, Hobday, Timothy, Moynihan, Timothy, Gillanders, William, Cyr, Amy, Eberlein, Timothy J, Hieken, Tina, Krontiras, Helen, Guo, Zhanfang, Lee, Michelle V, Spies, Nicholas C, Skidmore, Zachary L, Griffith, Obi L, Griffith, Malachi, Thomas, Shana, Bumb, Caroline, Vij, Kiran, Bartlett, Cynthia Huang, Koehler, Maria, Al-Kateb, Hussam, Sanati, Souzan, Ellis, Matthew J

Volltext

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer von Ma, Cynthia X, Bose, Ron, Gao, Feng, Freedman, Rachel A, Telli, Melinda L, Kimmick, Gretchen, Winer, Eric, Naughton, Michael, Goetz, Matthew P, Russell, Christy, Tripathy, Debu, Cobleigh, Melody, Forero, Andres, Pluard, Timothy J, Anders, Carey, Niravath, Polly Ann, Thomas, Shana, Anderson, Jill, Bumb, Caroline, Banks, Kimberly C, Lanman, Richard B, Bryce, Richard, Lalani, Alshad S, Pfeifer, John, Hayes, Daniel F, Pegram, Mark, Blackwell, Kimberly, Bedard, Philippe L, Al-Kateb, Hussam, Ellis, Matthew J C

Volltext

Railroads, specialization, and population growth: evidence from the first globalization von Forero, Andrés, Gallego, Francisco A., González, Felipe, Tapia, Matías

Volltext

Trastuzumab-Resistant HER2 + Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition von Wielgos, Monica E, Zhang, Zhuo, Rajbhandari, Rajani, Cooper, Tiffiny S, Zeng, Ling, Forero, Andres, Esteva, Francisco J, Osborne, C Kent, Schiff, Rachel, LoBuglio, Albert F, Nozell, Susan E, Yang, Eddy S

Volltext

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015 von O’Donnell, Peter H., Trubetskoy, Vassily, Nurhussein-Patterson, Ashley, Hall, Julianne P., Nath, Aritro, Huo, Dezheng, Fleming, Gini F., Ingle, James N., Abramson, Vandana G., Morrow, P. K., Storniolo, Anna Maria, Forero, Andres, Van Poznak, Catherine, Liu, Minetta C., Chang, Jenny C., Merkel, Douglas E., Peppercorn, Jeffrey M., Rugo, Hope S., Dees, E. Claire, Hahn, Olwen M., Hoffman, Philip C., Rosner, Gary L., Huang, R. Stephanie, Ratain, Mark J., Cox, Nancy, Olopade, Olufunmilayo I., Wolff, Antonio C., Dolan, M. Eileen, Nanda, Rita

Volltext

Phase II Trial of Bicalutamide in Patients with Androgen Receptor―Positive, Estrogen Receptor―Negative Metastatic Breast Cancer von GUCALP, Ayca, TOLANEY, Sara, STEARNS, Vered, DOANE, Ashley S, DANSO, Michael, MOYNAHAN, Mary Ellen, MOMEN, Lamia F, GONZALEZ, Joseph M, AKHTAR, Arooj, GIRI, Dilip D, PATIL, Sujata, FEIGIN, Kimberly N, ISAKOFF, Steven J, HUDIS, Clifford A, TRAINA, Tiffany A, INGLE, James N, LIU, Minetta C, CAREY, Lisa A, BLACKWELL, Kimberly, RUGO, Hope, NABELL, Lisle, FORERO, Andres

Volltext

Physical Activity and Sleep Quality in Breast Cancer Survivors: A Randomized Trial von ROGERS, LAURA Q, COURNEYA, KERRY S, OSTER, ROBERT A, ANTON, PHILIP M, ROBBS, RANDALL S, FORERO, ANDRES, MCAULEY, EDWARD

Volltext

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade von Prat, Aleix, Pascual, Tomás, De Angelis, Carmine, Gutierrez, Carolina, Llombart-Cussac, Antonio, Wang, Tao, Cortés, Javier, Rexer, Brent, Paré, Laia, Forero, Andres, Wolff, Antonio C, Morales, Serafín, Adamo, Barbara, Brasó-Maristany, Fara, Vidal, Maria, Veeraraghavan, Jamunarani, Krop, Ian, Galván, Patricia, Pavlick, Anne C, Bermejo, Begoña, Izquierdo, Miguel, Rodrik-Outmezguine, Vanessa, Reis-Filho, Jorge S, Hilsenbeck, Susan G, Oliveira, Mafalda, Dieci, Maria Vittoria, Griguolo, Gaia, Fasani, Roberta, Nuciforo, Paolo, Parker, Joel S, Conte, PierFranco, Schiff, Rachel, Guarneri, Valentina, Osborne, C Kent, Rimawi, Mothaffar F

Volltext

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexp... von RIMAWI, Mothaffar F, MAYER, Ingrid A, SCHIFF, Rachel, KENT OSBORNE, C, CHANG, Jenny C, FORERO, Andres, NANDA, Rita, GOETZ, Matthew P, RODRIGUEZ, Angel A, PAVLICK, Anne C, TAO WANG, HILSENBECK, Susan G, GUTIERREZ, Carolina

Volltext

Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated With Neoadjuvant Systemic Treatment for Operable Breast Cancer: Translational Breast Cancer Res... von DE LOS SANTOS, Jennifer F, CANTOR, Alan, MESZOELY, Ingrid M, NANDA, Rita, HWANG, E. Shelley, AMOS, Keith D, FORERO, Andres, GOLSHAN, Mehra, HORTON, Janet K, HUDIS, Clifford A, HYLTON, Nola M, MCGUIRE, Kandace, MERIC-BERNSTAM, Funda

Volltext

Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negati... von MAYER, Ingrid A, ABRAMSON, Vandana G, CANTLEY, Lewis C, WINER, Eric, ARTEAGA, Carlos L, ISAKOFF, Steven J, FORERO, Andres, BALKO, Justin M, KUBA, María Gabriela, SANDERS, Melinda E, YAP, Jeffrey T, VAN DEN ABBEELE, Annick D, YISHENG LI

Volltext

Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1 von McCaw, Tyler R., Li, Mei, Starenki, Dmytro, Liu, Mingyong, Cooper, Sara J., Arend, Rebecca C., Forero, Andres, Buchsbaum, Donald J., Randall, Troy D.

Volltext

The landscape of new drugs in lymphoma von Younes, Anas, Ansell, Stephen, Fowler, Nathan, Wilson, Wyndham, de Vos, Sven, Seymour, John, Advani, Ranjana, Forero, Andres, Morschhauser, Franck, Kersten, Marie Jose, Tobinai, Kensei, Zinzani, Pier Luigi, Zucca, Emanuele, Abramson, Jeremy, Vose, Julie

Volltext

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer von Yardley, Denise A, Weaver, Robert, Melisko, Michelle E, Saleh, Mansoor N, Arena, Francis P, Forero, Andres, Cigler, Tessa, Stopeck, Alison, Citrin, Dennis, Oliff, Ira, Bechhold, Rebecca, Loutfi, Randa, Garcia, Agustin A, Cruickshank, Scott, Crowley, Elizabeth, Green, Jennifer, Hawthorne, Thomas, Yellin, Michael J, Davis, Thomas A, Vahdat, Linda T

Volltext

Management of Metastatic Breast Cancer with Second-Generation Antibody–Drug Conjugates: Focus on Glembatumumab Vedotin (CDX-011, CR011-vcMMAE) von Vaklavas, Christos, Forero, Andres

Volltext

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study von Visvanathan, Kala, Fackler, MaryJo S, Zhang, Zhe, Lopez-Bujanda, Zoila A, Jeter, Stacie C, Sokoll, Lori J, Garrett-Mayer, Elizabeth, Cope, Leslie M, Umbricht, Christopher B, Euhus, David M, Forero, Andres, Storniolo, Anna M, Nanda, Rita, Lin, Nancy U, Carey, Lisa A, Ingle, James N, Sukumar, Saraswati, Wolff, Antonio C

Volltext

Recurrent read-through fusion transcripts in breast cancer von Varley, Katherine E., Gertz, Jason, Roberts, Brian S., Davis, Nicholas S., Bowling, Kevin M., Kirby, Marie K., Nesmith, Amy S., Oliver, Patsy G., Grizzle, William E., Forero, Andres, Buchsbaum, Donald J., LoBuglio, Albert F., Myers, Richard M.

Volltext

TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer von Rimawi, Mothaffar F, Niravath, Polly, Wang, Tao, Rexer, Brent N, Forero, Andres, Wolff, Antonio C, Nanda, Rita, Storniolo, Anna M, Krop, Ian, Goetz, Matthew P, Nangia, Julie R, Jiralerspong, Sao, Pavlick, Anne, Veeraraghavan, Jamunarani, De Angelis, Carmine, Gutierrez, Carolina, Schiff, Rachel, Hilsenbeck, Susan G, Osborne, C Kent

Volltext